Trending Now
Agenus Inc (NASDAQ: AGEN) Inks Licensing Deal With Bristol-Myers Squibb Co...
Agenus Inc (NASDAQ: AGEN) has partnered with Bristol-Myers Squibb Co (NYSE: BMY). As part of the agreement, Bristol Myers Squibb Co will study an...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
atai Life Sciences N.V. (NASDAQ: ATAI) Receives FDA Clearance For IND...
atai Life Sciences N.V. (NASDAQ: ATAI) has announced that the US FDA has given it an Investigational New Drug approval to carry a clinical...
MAKE IT MODERN
LATEST REVIEWS
Timber Pharmaceuticals Inc. (NYSEAMERICAN: TMBR) Announce Encouraging Top-Line Results Evaluating TMB-001...
Timber Pharmaceuticals Inc. (NYSEAMERICAN: TMBR) has announced promising top-line data from the phase 2b CONTROL study evaluating TMB-001 in treating moderate to severe congenital...
MAKE IT MODERN
PERFORMANCE TRAINING
Actinium Pharmaceuticals (ATNM) Gains Momentum: Strategic KOL Call Scheduled Amid Radiopharma Sector’s M&A Surge
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a pioneer in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapies, is set to...
Cocrystal Pharma Inc (NASDAQ: COCP)’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Vitro Activity Against...
The SARS-CoV-2 3CL protease lead CDI-45295 and several analogs of Cocrystal Pharma Inc (NASDAQ: COCP) showed potent in broad-spectrum vitro activity against the SARS-CoV-2...
British Journal of Haematology Publishes Post-Hoc Analysis of Tavalisse for Adults with Chronic Immune...
The COVID-19 global pandemic is biting harder by the day, and it seems like it is here to stay. Hence there remains a serious...
Reason why Enzo Biochem (NYSE:ENZ) surged on Friday
Enzo Biochem, Inc. (NYSE:ENZ) last traded at $2.2500, a gain of $1.0600 (+89.08%). The previous close was at 1.1900, while the open reached...
Galera Therapeutics Inc (NASDAQ:GRTX) Reports Updated Results Of Phase 1/ 2 Pilot Study Of...
Galera Therapeutics Inc (NASDAQ:GRTX) issued an update on multi-centre, double-blind, randomized and placebo-controlled Phase 1/2 clinical study results of GC4419 in SBRT treated patients...
MAKE IT MODERN
